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Background:  ECCO  essential  requirements  for quality  cancer  care  (ERQCC)  are  checklists  and  explanations
of  organisation  and  actions  that  are  necessary  to give  high-quality  care  to patients  who  have  a  speciﬁc
tumour  type.  They  are  written  by European  experts  representing  all disciplines  involved  in cancer  care.
ERQCC  papers  give  oncology  teams,  patients,  policymakers  and  managers  an overview  of the  elements
needed  in any  healthcare  system  to provide  high  quality  of  care  throughout  the  patient  journey.  Refer-
ences  are  made  to clinical  guidelines  and other  resources  where  appropriate,  and  the  focus  is on  care  in
Europe.
Colorectal cancer:  essential  requirements  for  quality  care
• Colorectal  cancer  (CRC)  is the  second  most  common  cause  of  cancer  death  in Europe  and  has  wide
variation  in outcomes  among  countries.  Increasing  numbers  of  older  people  are  contracting  the  disease,
and  treatments  for advanced  stages  are  becoming  more  complex.  A growing  number  of  survivors  also
require  specialist  support.
• High-quality  care  can only  be a carried  out  in specialised  CRC  units  or  centres  which  have  both  a core
multidisciplinary  team  and  an  extended  team  of allied  professionals,  and  which  are  subject  to  quality
and  audit  procedures.  Such  units  or centres  are  far from  universal  in  all European  countries.
• It is  essential  that,  to  meet  European  aspirations  for  comprehensive  cancer  control,  healthcare
organisations  implement  the  essential  requirements  in  this  paper,  paying  particular  attention  to  mul-
tidisciplinarity  and patient-centred  pathways  from  diagnosis,  to  treatment,  to  survivorship.
Conclusion:  Taken  together,  the  information  presented  in this  paper  provides  a comprehensive  description
of  the  essential  requirements  for  establishing  a  high-quality  CRC  service.  The  ECCO  expert  group  is aware
that it is not  possible  to  propose  a ‘one  size  ﬁts  all’ system  for all countries,  but urges  that  access  to
multidisciplinary  units  or  centres  must  be guaranteed  for  all those  with  CRC.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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was 12.2% of all deaths from cancer in Europe (Ferlay et al., 2013a).
• CRC is the second most common cancer in women and the third
in men, although the number of men  who  are diagnosed and dieG. Beets et al. / Critical Reviews in O
reamble
ECCO essential requirements for quality cancer care (ERQCC)
re checklists and explanations of organisation and actions that are
ecessary to give high-quality care to patients who  have a speciﬁc
umour type.
They are primarily organisational recommendations, not clini-
al guidelines, and are intended to give oncology teams, patients,
olicymakers and managers, an overview of the elements needed
n any healthcare system to provide high quality of care through-
ut the patient journey. References are made to clinical guidelines
nd other resources where appropriate, and the focus is on care in
urope.
The foundation of this ECCO requirements series is the concept
f quality, which has become increasingly important in all aspects
f healthcare, as the population has increasing number of older
eople needing care, as many new and complex treatments come
nto use, and as more pressure is put on using resources effectively.
olicymakers and patients need to know that their healthcare
orkforce, technology and facilities are conﬁgured optimally for
ach illness. In this context, improving quality of cancer care means
elivering care that is timely, safe, effective and efﬁcient; puts the
atient at the centre of care; and gives all people equal access to
igh-quality care.
The structure of the ECCO ERQCC series is the same for each
umour type:
Introduction: why we need cancer quality frameworks
Key facts and challenges associated with the tumour type from
diagnosis to treatment
Organisation of care: an overview of the patient pathway and
overall requirements to deliver care
Multidisciplinary working: in more detail, the requirements for
core and ‘expanded’ teams involved in the patient pathway
Measurement and accountability: quality assurance and audit,
patient involvement and access to information.
ssential requirements for quality cancer care: colorectal
ummary points
Colorectal cancer (CRC) is the second most common cause of can-
cer death in Europe and has wide variation in outcomes among
countries. Increasing numbers of older people are contracting the
disease, and treatments for advanced stages are becoming more
complex. A growing number of survivors also require specialist
support.
High-quality care can only be a carried out in specialised CRC units
or centres which have both a core multidisciplinary team and an
extended team of allied professionals, and which are subject to
quality and audit procedures. Such units or centres are far from
universal in all European countries.
It is essential that, to meet European aspirations for compre-
hensive cancer control, healthcare organisations implement the
essential requirements in this paper, paying particular attention
to multidisciplinarity and patient-centred pathways from diag-
nosis, to treatment, to survivorship.
. Introduction: why we need quality frameworks
There has been a growing emphasis on driving up quality in
ancer organisations, given that there is wide agreement that much
are is not accessible, not well coordinated and not based on current
vidence. This is the starting point of a report by the US Institute
f Medicine (IOM) in 2013 (Levit et al., 2013), which is blunt in
escribing a ‘crisis in cancer care delivery’, as the growing numbergy/Hematology 110 (2017) 81–93 83
of older people will mean rising cancer incidence and numbers of
survivors, while there are pressures on workforces amid rising costs
of care and complexity of treatments.
Not least, the IOM notes that the few tools currently available
for improving the quality of cancer care − quality metrics, clinical
practice guidelines, and information technology − are not widely
used and all have serious limitations.
An assessment of the quality of cancer care in Europe was made
as part of the ﬁrst EU Joint Action on Cancer, the European Part-
nership for Action Against Cancer (EPAAC, http://www.epaac.eu),
which reported in 2014 that there are important variations in ser-
vice delivery between and within countries, with repercussions for
quality of care. Factors such as waiting times and provision of opti-
mal  treatment can explain about a third of the differences in cancer
survival, while cancer plans, such as with a national cancer plan
that promotes clinical guidelines, professional training and quality
control measures, may  be responsible for a quarter of the survival
differences.
EPAAC paid particular attention to the importance of providing
multidisciplinary care for each tumour type, going as far as to issue
a policy statement (Borras et al., 2014) that emphasised the impor-
tance of team working, as cancer care is undergoing a ‘paradigm
shift’ from a disease-based approach to a patient centred one, in
which increasingly more attention is paid to psychosocial aspects,
quality of life, patients’ rights and empowerment, comorbidities
and survivorship. EPAAC further focused on the establishment of
networks of expertise in regions where it is not possible to establish
comprehensive centres.
The EU Joint Action on Cancer Control (CANCON, http://www.
cancercontrol.eu), which replaced EPAAC from 2014, is also focus-
ing on quality of cancer care and is due to publish in 2017 the
European Guide on Quality Improvement in Comprehensive Cancer
Control.
Countries have been concentrating expertise for certain tumour
types in dedicated centres, or units, such as for childhood and rare
cancers, and most comprehensive cancer centres have teams for the
main cancer types. For common adult tumours, however, at Euro-
pean level there has been widespread effort to establish universal,
dedicated units only for breast cancer, following several European
declarations that set a target of the year 2016 for such care of
all women  and men  with breast cancer to be treated in specialist
multidisciplinary centres. While this target has been far from met
(Cardoso et al., 2016), the view of ECCO’s essential requirements
expert group is that the direction of travel is for all main tumour
types to adopt the principles of such dedicated care.
For colorectal cancer (CRC), this means establishing the care
pathways and multidisciplinary teams that are described in this
document, and also the same approach to auditing, quality assur-
ance and accreditation of a ‘unit’ than is emerging in breast cancer,
and indeed for CRC in some European countries.
2. Colorectal cancer (CRC): key facts and challenges
2.1. Key facts
• CRC is a common cancer and the second most common cause of
cancer death in Europe (after lung cancer). In 2012, about 447,000
new cases and 215,000 deaths from CRC were estimated, whicheach year in Europe is higher than women (in 2012, there were
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survivors suffer for many years from ongoing conditions that
result from the primary treatment of their cancer, such as a4 G. Beets et al. / Critical Reviews in O
about 242,000 new cases in men, 205,000 in women; deaths in
that year were 113,000 and 101,000). The risk of contracting CRC
for people under the age of 75 in 2012 was 3.51% in Europe (4.48%
men, 2.73% women) (Ferlay et al., 2013b).
In 2012, the 5-year prevalence of CRC (those alive 5 years after
diagnosis), was about 1.2 million in Europe, showing that there
is a large population of survivors. The 5-year survival rate for
Europe was 57% for colon and 56% for rectal cancer according to
the Eurocare-5 study (Holleczek et al., 2015). The 5-year survival
rate is associated with the stage of CRC at diagnosis, broadly: 90%
for local stages, 50% for disease that has spread to lymph nodes,
and 10–20% for metastatic disease.
.1.1. Risk factors and prevention
Risk factors include family history, including inherited disorders;
a history of polyps in the bowel and inﬂammatory bowel disease;
lifestyle factors; and age: more than 90% of CRC is diagnosed in
people in their 50s and older.
The risk of developing CRC can be reduced by:
© Avoiding obesity and weight gain around the midsection
© Not smoking
© Increasing the intensity and amount of physical activity
© Limiting intake of red and processed meats
© Eating more vegetables and fruits
© Getting the recommended levels of calcium and vitamin D
© Avoiding excess alcohol
© See for example: American Cancer Society. Can colorec-
tal cancer be prevented? http://www.cancer.org/cancer/
colonandrectumcancer/detailedguide/colorectal-cancer-
prevention.
.1.2. Screening
CRC is one of the few cancers that have evidence for population
screening (breast and cervical are the others). Most CRC develops
from benign polyps, which can be removed during a colonoscopy.
In 2003, the Council of the European Union called on member
states to implement screening programmes for CRC in all EU
countries.
The ECCO expert group supports the importance of screening in
the prevention and early detection of CRC and also calls on EU
member states to ensure that appropriate policies are adopted
across Europe to ensure that efﬁcient CRC screening programmes
are implemented.
.1.3. Diagnosis and treatment
Symptoms that often lead to a diagnosis of CRC are change in
bowel habit, anaemia, fatigue, rectal bleeding and an abdominal
mass. However, as most patients are asymptomatic, screening is
of great importance.
Investigations to detect CRC are colonoscopy, sigmoidoscopy (for
the lower colon) and computed tomography (CT) colonography
(also called virtual colonoscopy). Biopsy and imaging/pathology
reports conﬁrm a diagnosis and the stage of the disease − like
most cancers, CRC is categorised into four clinical stages accord-
ing to Union for International Cancer Control (UICC) classiﬁcation,
from localised to the lining of the colon (stage 1) to spread to other
organs (stage 4, or metastatic disease).
Treatment: most patients with localised (early and locally
advanced) CRC have surgery to remove the tumour and any
affected lymph nodes. Radiotherapy is used pre-operatively in
rectal cancer, but not often in colon cancer as too much healthy
tissue can be exposed. Chemotherapy is usually offered post-
operatively to people with localised disease with lymph node
involvement to reduce the risk of a recurrence. Patients with
metastatic disease should receive systemic treatment, includinggy/Hematology 110 (2017) 81–93
targeted therapies, depending on characteristics of their disease
(including molecular biology). In selected cases, treatment for
metastatic disease can include local treatment (surgery, radio-
therapy, interventional radiology) and can aim to be curative.
2.2. Challenges in CRC care
2.2.1. Inequalities
• Countries in Eastern and Central Europe have the lowest survival
rates for CRC. In the Eurocare-5 study (Ferlay et al., 2013a), the
highest 5-year survival for colon cancer was found for patients
in Belgium, Germany and Iceland (62%) and lowest for patients
in Latvia (43%) (but lower survival than the 57% European aver-
age was  also observed for patients in Denmark (54%) and Croatia
(50%)). For rectal cancer, the highest survival was for patients
in Belgium and Switzerland (63%) and lowest for those in Latvia
(36%), but low survival was  also observed for Croatia (49%) and
Slovenia (50%).
• Discrimination by age is signiﬁcant in CRC because the majority
of cases are among older people − about 60% of cases are in those
aged 70 and over, with the highest incidence in people in their
mid- to late-80s. Providing the current standard of care to older
people in all cancers is important and is particularly challenging
in CRC, because of the numbers and because there can be sev-
eral co-morbidities to manage, and consistent partnership with
geriatric specialists can be needed.
2.2.2. Diagnosis and screening
• Embarrassment and stigma: in some countries and cultures there
can be a reluctance to bother doctors, usually primary care GPs,
with symptoms of CRC. There is potential to do much more
awareness raising on CRC that can involve policymakers, health
professionals and patient groups.
• Screening programmes differ widely across Europe. Only a minor-
ity of countries have rolled out population screening; others have
‘opportunistic’, pilot or no programmes.
2.2.3. Treatment
• CRC, as one of the major cancers, is treated by a wide range
of healthcare providers but not necessarily by multidisciplinary
units and according to guidelines and recognised care pathways.
• Some patients with metastatic CRC can be cured but do not always
get the multidisciplinary assessment they should. For the major-
ity of metastatic CRC patients, who cannot be cured, treatment is
particularly challenging because of the complex and wide range
of treatment options, and for which there are varying grades of
evidence of effectiveness. Awareness and availability of treat-
ment options such as targeted therapy also varies among and
within countries. In CRC, this is exempliﬁed by campaigns that
promote greater awareness of metastatic disease options and
testing for biomarkers to determine whether certain therapies are
beneﬁcial (for example, Get Personal, http://www.getpersonal.
global).
2.2.4. Survivorship
• The number of cancer survivors is rising quickly, and some CRCpermanent stoma, bowel and urinary problems, and sexual dys-
function (Jansen et al., 2011). Specialist supportive care for a
growing population of CRC survivors is becoming a major issue.
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. Organisation of care
Essential requirements for the organisation of CRC care encom-
ass:
Cancer care pathways
Timelines of care
Minimum case volumes
Multidisciplinary teamworking among core and extended groups
of professionals, in a dedicated CRC centre or unit
Audit, performance measurement, quality assurance of outcomes
and care
Professional education, enrolment in clinical trials and delivery
of patient information.
These topics are outlined in the following sections, with refer-
nce to national and European resources and clinical guidelines,
here appropriate.
.1. Care pathways and timelines
Care for colorectal cancer patients should be organised in care
pathways that chart the patient’s journey from their perspective
rather than that of the healthcare system. (The European Pathway
Association deﬁnes a care pathway as “a complex intervention for
the mutual decision making and organisation of care processes for
a well-deﬁned group of patients during a well-deﬁned period”.
This broad deﬁnition covers terms such as clinical, critical, inte-
grated and patient pathways that are also often used. See http://
e-p-a.org/care-pathways.) Pathways should incorporate current
evidence set out in national and European guidelines. An exem-
plar of a CRC pathway is the National Institute for Health and
Care Excellence (NICE) pathway (NICE Pathways, Colorectal can-
cer overview. http://pathways.nice.org.uk/pathways/colorectal-
cancer). As the NICE guidance makes clear, the overall pathway
for CRC comprises only a few main subsidiary pathways − sus-
pected CRC and referral, information and support for patients,
diagnosis, staging, and cancer treatment management.
Primary care practitioners are the usual referrers of those with
suspected CRC and need timely access to hospital specialists
and typically a diagnosis is established by endoscopy. In Eng-
land and Wales, the maximum time for an appointment to check
suspected symptoms of all cancers is 2 weeks (NICE Pathways.
Suspected cancer recognition and referral: Gastrointestinal tract
(lower) cancers. http://bit.ly/2gzGU58). Suspected CRC identiﬁed
through faecal occult screening programmes is referred in the
same time (2 weeks). Other countries have shorter targets: in
the Netherlands, the maximum time for an appointment when
a malignancy is suspected is 1 week. The ECCO expert group
strongly recommends that countries ensure that waiting times
are below these times as is the case in several European countries
that make urgent referrals within 48 h.
A comprehensive examination of screening and diagnosis is avail-
able in ‘European guidelines for quality assurance in colorectal
cancer screening and diagnosis’ (European Commission, 2010). In
England and Wales, about 10% of patients with CRC are currently
diagnosed through screening, and 55% following GP referral
(Healthcare Quality Improvement Partnership, 2015).
Times to report a diagnosis of CRC and the opportunity to start
treatment are crucial to the wellbeing of patients to avoid as much
anxiety as possible. Guidelines in the Netherlands, for example,
state that the maximum time for diagnostic and staging proce-
dures is 3 weeks, and the maximum time from ﬁrst appointment
to ﬁrst treatment is 6 weeks.
After a diagnosis, it must be clear to the patient which profes-
sional is responsible for each step in the treatment pathways andgy/Hematology 110 (2017) 81–93 85
who is following the patient during the journey (usually called
a case manager or patient navigator). In many countries, case
managers during the main stages of treatment are cancer nurses
(Borras et al., 2014), with some being specialists in CRC. There
must also be a medical professional responsible for coordinating
treatment modalities and specialties, namely the lead oncology
specialist. This is usually a surgeon or medical oncologist, depend-
ing on local agreements and the stage of the disease.
• Some patients with CRC present as emergencies with an intesti-
nal obstruction or perforation (this can be a signiﬁcant number
in some countries − about 20% of CRC patients in England and
Wales). While it is preferable for these patients to be treated by
the colorectal team from the start, this is often not possible but
care must be transferred to the colorectal team straight after the
emergency procedure.
• Follow-up and survivorship are major issues in CRC. Typically,
care pathways include surveillance for cancer recurrence but
patients often have to seek help elsewhere for long term side-
effects of treatment, by going to both acute and community
facilities. Continuity and integration of all care must be imple-
mented as gaps in long-term care can cause much distress (Jansen
et al., 2010).
3.2. CRC centres/units: requirements
• It is essential for all patients to be treated in a multidisciplinary
centre; that members of the multidisciplinary team see a cer-
tain annual number of cases; and that members of the core team
dedicate signiﬁcant time to treating patients with CRC, although
requirements vary according to the various disciplines. Based on
the existing evidence, the ECCO expert group recommends that
for a hospital to be considered as a CRC centre it should manage
at least 100 new CRC cases a year.
• There are three patient categories that usually require different
levels of expertise and infrastructure:
© Uncomplicated primary colorectal cancer
• Locally advanced or recurrent disease
• Metastatic disease.
• The expertise required for advanced cases often concerns certain
surgery, radiotherapy and specialist interventions, and a CRC unit
that does not have this expertise or facilities should have close
referral cooperation with centres that provide them.
• All CRC units must have a follow-up programme in place in accor-
dance with guidelines.
3.3. The multidisciplinary team
Treatment strategies for all patients must be decided on,
planned and delivered as a result of consensus among a core mul-
tidisciplinary team (MDT) that comprises the most appropriate
members for the particular diagnosis and stage of cancer, patient
characteristics and preferences, and with input from the extended
community of professionals. The heart of this decision making pro-
cess is normally a weekly or more frequent MDT  meeting where
patients are discussed with the objective of balancing the recom-
mendations of clinical guidelines with the ‘reality’ of the individual
patient.
To properly treat CRC it is essential to have a core MDT of dedi-
cated health professionals from the following disciplines:• Gastroenterology/endoscopy
• Pathology
• Radiology/imaging
• Surgery
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Radiotherapy
Medical oncology
Interventional radiology
Nursing.
This core MDT  must discuss:
All new patients after diagnosis and staging to decide on optimal
treatment
Patients after major treatment, usually surgery, to decide on fur-
ther treatment (such as adjuvant chemotherapy) and follow-up
Patients with a recurrence during follow-up to decide on optimal
treatment.
In CRC, there are certain patients who do not need to be dis-
ussed at a full MDT  meeting:
Cases with a clear decision algorithm, such as early tumours (T1
stage disease), and advanced adenomas (benign polyps in the
colon) usually require only gastroenterologists, pathologists and
surgeons
Those with widespread and incurable metastatic disease may
need only radiologists, radiation oncologists, surgeons, medical
oncologists and palliative care specialists.
The pre-requisite is a clinical pathway for each category that
lso determines when patients must be discussed at a full multi-
isciplinary tumour board.
Healthcare professionals from the following disciplines must
e available whenever their expertise is required (the ‘expanded’
DT):
Nuclear medicine
Oncology pharmacy
Geriatric oncology
Psycho-oncology
Diet and nutrition
Palliative care
Rehabilitation and survivorship
Neuro-oncology.
All discussions have to be minuted and decisions documented in
 comprehensive and understandable manner, and should become
art of patient records. Weekly MDT  meetings must be minuted
nd the annual internal audit must be incorporated into quality
earning systems as they develop.
It is essential that all relevant patient data, such as pathology
eports, meet quality standards and are available at the time of the
DT  meeting.
. Disciplines within the core MDT
.1. Gastroenterology and endoscopy
The role of the gastroenterologist/endoscopist is to:
Advise on all means of primary and secondary prevention of CRC
Perform relevant colonoscopies (including after surgery if
needed) and palliative procedures when required, such as colonic
stents
Treat polyps and early lesions
Identify and follow up patients at high risk for of developing CRC
Manage long- and short-term gastrointestinal side-effects of
treatmentgy/Hematology 110 (2017) 81–93
• In some countries and settings, gastroenterologists are also
responsible for systemic therapy (see also section on medical
oncology).
• A gastroenterologist/endoscopist must have a qualiﬁcation in
diagnostic and interventional colonoscopy (e.g. according to
number of procedures performed a year, completeness of pro-
cedures, adenoma detection rate, number of polyps removed,
as speciﬁed by country regulations) (Kamin´ski et al., 2014; Rees
et al., 2016; Bretthauer et al., 2016).
• In countries where systemic treatment of gastrointestinal cancer
is carried out by gastroenterologists, they must have a qualiﬁ-
cation and expertise in the systemic treatment of CRC and the
management of side-effects (e.g. as demonstrated by a certain
number of chemotherapeutic cycles and targeted agents given
each year). They must also follow up after surgery to make sure
that adjuvant treatment, for example, is applied whenever it is
indicated.
4.2. Pathology
Pathology, including molecular pathology, is playing an increas-
ingly critical role in the diagnosis of CRC. The role of the pathologist
is to conduct a detailed study of the tumour based on the sam-
ple taken from the biopsy and to prepare a pathology report for
discussion at the MDT.
Essential requirements:
• The pathologist must have expertise in reporting on CRC preoper-
ative biopsies and surgical specimens: they must know recently
published guidelines and reviews on pathological CRC reporting
(Nagtegaal, 2015) and their pathology reports must contain a list
of items as recommended by professional organisations (Quirke
et al., 2011). The use of structured (or synoptic) reports is strongly
encouraged (see examples from the Royal College of Pathology
in the UK and the Royal College of Pathologists of Australasia)
(Loughrey et al., 2014; Royal College of Pathologists of Australasia,
2013).
• With the increasing importance of molecular data in therapeutic
decisions, access to an accredited molecular pathology laboratory
must be guaranteed, although it may  not be on site.
4.3. Radiology/imaging
Radiology/imaging plays a critical role in diagnosing (includ-
ing screening), staging and follow-up of CRC, and personalised
treatment. The role of the radiologist is to perform radiology pro-
cedures for screening, diagnosis, staging and follow-up of CRC
using the most appropriate imaging test depending on the clini-
cal scenario (including cancer location and clinical presentation,
i.e., emergency, elective).
Essential requirements:
• The radiologist must have expertise in gastrointestinal imaging
• For rectal cancer, they must know the advantages and limita-
tions of -trans-rectal ultrasound and magnetic resonance (MR)
imaging in primary staging and must be able to integrate imaging
data with colonoscopy data. They must also know how to assess
response after neoadjuvant rectal cancer therapy. This is an evolv-
ing area where integration of radiologic, clinical and endoscopic
data is mandatory (Beets-Tan et al., 2013)
• As colon cancer staging is based mainly on computed tomography
(CT) ﬁndings, knowledge of state-of-the-art CT protocols, includ-
ing CT colonography (also called virtual colonoscopy) (Neri et al.,
2013) is required. Expertise in liver contrast-enhanced ultra-
sound (CEUS) and MR  imaging, with the use of hepato-speciﬁc
contrast agents, is also needed as these methods may  be neces-
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sary to characterise a focal liver lesion and to provide a disease
balance before surgery for liver metastases (van Kessel et al.,
2012)
The radiologist must know when to refer a patient to nuclear
medicine for positron emission tomography (PET)-CT. In that
case, nuclear medicine physicians and radiologists must liaise to
allow joint patient management, reading and reporting.
.4. Surgery
Treatment of primary presentation of CRC requires surgery in
0–90% of patients. For patients with metastatic disease and local
ecurrence, surgery can also be an important part of the treatment.
he role of the surgeon is to coordinate the surgical procedure and
erioperative care and to perform appropriate surgery as decided
n the MDT. In addition, the surgeon can also be the lead oncology
pecialist who coordinates treatment modalities, mostly in patients
ho are treated with curative intent.
Essential requirements:
Surgeons must have expertise in the type of CRC operations they
carry out, as there are different requirements for surgical treat-
ment according to the tumour. There are no current guidelines
on the minimum number of procedures for each surgeon, but
some countries recommend minimum numbers per centre, for
example Dutch guidelines state that 50 colonic resections and
20 rectal resections per year per institution should be a min-
imum requirement for surgery. Locally advanced rectal cancer
and metastatic CRC procedures on the liver, lung and peritoneum
must be carried out in centres that have the required infrastruc-
ture, with a minimum volume of 20 surgical procedures for each
procedure (Van Leersum et al., 2013; SONCOS (Dutch foundation
for oncological collaboration), 2016; National Institute for Health
and Care Excellence, 2014; Are et al., 2016)
There must be at least two experienced colorectal surgeons who
dedicate a signiﬁcant proportion of their time to colorectal pro-
cedures, including cancer surgery
There must be perioperative care programmes that include
anaesthesiologists, nurses and dieticians
An intensive care unit must be available on-site.
.5. Radiotherapy
Radiotherapy is often used before surgery in rectal cancer to
acilitate curative resection with clear margins and to reduce the
isk of local recurrence. It can be selectively used after surgery in a
mall minority of patients with high risk factors for local recurrence
ho did not receive pre-operative treatment. Decision-making is
ultidisciplinary and takes many factors into account (Valentini
t al., 2014; Glimelius et al., 2013; National Institute for Health and
are Excellence, 2014). Radiotherapy can also help control cancers
n people who are not healthy enough for surgery or to ease (palli-
te) symptoms in people with advanced cancer that has caused an
ntestinal blockage, bleeding or pain.
Radiation oncologists are responsible for patients’ ongoing care
nd wellbeing, according to these clinical situations. They also
etermine and prescribe the most suitable dose fractionation of
adiation in keeping with national and international guidelines.
Essential requirements:Access to radiotherapy must be provided in the centre or through
a formal, collaborative agreement
The radiotherapy centre must have agreed protocols for radio-
therapy and concurrent chemo-radiotherapy for rectal cancergy/Hematology 110 (2017) 81–93 87
and clearly describe their image guidance policy and quality
assurance guidelines
• Access to 3D conformal RT and IMRT, where clinically indicated,
must be available and delivered according to clearly deﬁned
protocols. Centres must have access to stereotactic ablative
radiotherapy (SABR) where clinically indicated and according to
agreed referral and treatment guidelines
• Radiation oncologists must be responsible for follow-up and
management of late toxicity and survivorship issues. Protocols
must be in place for the management of late toxicity including
bowel, urinary and sexual dysfunction.
4.6. Medical oncology
Medical oncology plays an important role in the general man-
agement of CRC patients − and speciﬁcally of CRC patients with
advanced and metastatic disease (stages 3 and 4) and in selected
high-risk patients with stage 2 disease. In these situations, the
medical oncologist is the lead oncology specialist. The role of the
medical oncologist is to:
• Coordinate all aspects of multimodal drug treatment, which
may  include coordination of clinical and molecular diagnos-
tics, and indication setting and distribution of treatment with
systemic therapies (such as chemotherapy, monoclonal antibod-
ies, signal-transduction inhibitors and, potentially in the future,
immunotherapies) and to carry out indication setting for mul-
timodal treatment and discuss treatment goals with the patient
and other professionals
• Initiate and coordinate symptom-related management in coop-
eration with specialists who  manage tumour or disease-related
symptoms (palliative and symptomatic treatment), and rehabil-
itation and survivorship.
Essential requirements:
• Medical oncologists treating CRC must have in-depth under-
standing of the prognostic and predictive clinical and molecular
factors that contribute to indication setting and treatment inten-
sity and duration of drug therapies. These factors comprise both
clinical risk factors and molecular factors and must be consid-
ered with clinical goals and other, non-disease related factors
and patient preferences. Medical oncology for CRC is increas-
ingly complex, as evidenced in the latest clinical guidelines for
metastatic disease (Labianca et al., 2013; Glimelius et al., 2013;
Van Cutsem et al., 2016)
• They must have in-depth knowledge of the interaction of cancer
speciﬁc treatments with other conditions (such as comorbidities
and their management). This includes supportive treatment for
management of pain, gastrointestinal symptoms and side-effects
of systemic therapy.
4.7. Interventional radiology
Interventional radiology plays a central role in the treatment of
patients with metastatic CRC. The role of the interventional radiol-
ogist is to:
• When indicated, perform biopsies on unclear hepatic, pulmonary
or musculoskeletal lesions• Participate in the MDT  to support combined therapies in patients
with metastatic disease, e.g. surgery and ablation or systemic
treatment and radioembolisation (for the latter, with the nuclear
medicine physician)
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Perform minimally-invasive therapies according to the MDT’s
decision.
Essential requirements:
The interventional radiologist must discuss the role and propose
use of local ablative techniques for treating liver or lung or bone
metastases not amenable to, or combined with, surgery or radio-
therapy
They must be able to perform not only percutaneous thermal
ablation (e.g. radiofrequency, microwave), but also transarterial
bland or transarterial chemoembolisation (including drug-
loaded particles), radioembolisation (e.g. yttrium-90 labelled
particles) and cementoplasty (Gillams et al., 2015; Tanis et al.,
2012; de Baère et al., 2015). A minimum of 100 interventions
a year is required for the German Certiﬁcate of Interventional
Radiology.
.8. Nursing
Nursing a person with CRC requires a range of roles. Nurses use
ommunication, technical and observation skills to conduct a holis-
ic assessment to identify and then address physical, psychological
nd social needs throughout the care pathway. They promote
atient autonomy and self-management where possible, through
ersonalised information and support. Due to the increasing com-
lexity of care, there is a requirement for highly-specialised cancer
ursing (National Cancer Action Team, 2010; Macmillan Cancer
upport, 2011). Extended nursing roles for CRC (often known as
urse practitioners) are now common in some countries and they
nclude performing endoscopy, stoma care, and delivering systemic
reatments and survivorship care, including organising surveillance
n consequences of treatment.
Essential requirements:
Nurses working in CRC centres must have insight into each
patient’s experience of their disease, treatment and side-effects
They must provide information and education to the patient and
family and be the point of contact for them where they act as case
managers
Nurses must act in the best interest of the patient and their family
to help coordinate the diagnosis, treatment and after-care of a
person with CRC
They must represent the patient’s psychosocial needs and pref-
erences within the MDT
Nurses must help make referrals to other services, such as to a
psychologist if there is a concern about distress.
. Disciplines in the expanded MDT
.1. Nuclear medicine
There is evidence for the efﬁcacy of FDG-PET and FDG-PET/CT in
elected clinical indications in CRC for restaging (detection of local
ecurrence (Maas et al., 2011), metastases (Mafﬁone et al., 2015),
ocal recurrence or metastases in the case of rising tumour mark-
rs with negative ﬁrst-line imaging with CT/MRT); and treatment
esponse evaluation (assessment of response of metastases after
hemotherapy, early assessment of metastases during chemother-
py, assessment of efﬁcacy of neoadjuvant therapy for advanced
ectal carcinoma, assessment of efﬁcacy of localised minimally
nvasive therapy).
The role of the nuclear medicine physician is to oversee all
spects of PET/CT for patients who require this procedure, includinggy/Hematology 110 (2017) 81–93
indications, multidisciplinary algorithms and management proto-
cols (Boellaard et al., 2015).
Essential requirements:
• Nuclear medicine physicians with expertise in PET must be avail-
able to the MDT. In 2016, most European hospitals have access
to PET/CT technology but it should preferably be on-site, be less
than 10 years old and ready for radiation treatment planning, and
have integrated PACS/RIS and updated workstations
• Conventional nuclear medicine must also be available
• Nuclear medicine must be able to perform daily veriﬁcation pro-
tocols and to react accordingly. Quality-assurance protocols must
be in place. An option for ensuring the high quality of PET/CT scan-
ners is provided by the European Association of Nuclear Medicine
(EANM) through EARL accreditation.
5.2. Geriatric oncology
As 60% of CRC patients are more than 70 years old and 43% over
75 and given that older individuals may  require adapted care and
prioritisation of health issues, geriatric oncology plays an important
role in care. The role of the geriatric oncologist is to:
• Ensure that older patients are screened for frailty
• Coordinate recommendations to other specialists about the need
for personalised treatment for frail patients.
Essential requirements:
• Geriatric oncologists must ensure all older patients are screened
with a simple risk-assessment frailty screening tool (Decoster
et al., 2015) with whenever possible an estimation of life
expectancy to allow prioritisation of medical interventions
(for example with the ePrognosis colorectal screening survey.
http://cancerscreening.eprognosis.org/screening)
• A ‘geriatric oncology team’ (including geriatricians and other
specialists) must be available for all frail patients and their evalu-
ation discussed in MDT  meetings to offer personalised treatment
(Papamichael et al., 2015)
• Geriatric oncologists must ensure the early integration of pal-
liative care plans or ‘geriatric interventions’, especially for frail
patients
• Organ preservation strategies for frail rectal cancer patients must
be discussed and implemented at the MDT. This includes a num-
ber of strategies with reduced invasiveness such as transanal
surgical techniques, ‘watchful waiting’ approach after chemora-
diation or locally applied endocavity contact radiation therapy.
5.3. Oncology pharmacy
Oncology pharmacy plays a critical role in the care of CRC
patients, given the importance of systemic treatment. The role of
the oncology pharmacist is to:
• Liaise with the medical oncologist to discuss pharmaceutical
treatment
• Supervise the preparation of oncology drugs.
Essential requirements:
• Oncology pharmacists must work closely with medical oncolo-
gists. They must have experience with interactions with other
drugs (CRC patients are often older people and so are likely to
have comorbidities); experience with dose adjustments based on
liver and kidney function; and knowledge of complementary and
alternative medicines. Oncology pharmacists must comply with
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the European QuapoS guidelines (European Society of Oncology
Pharmacy, 2014)
Oncology drugs must be prepared in the pharmacy and dis-
pensing must take place under the supervision of the oncology
pharmacis
.4. Psycho-oncology
About 30% of colorectal cancer patients suffer from severe psy-
hosocial distress: 60% reported mild to severe levels of depression,
nd 52% mild to severe levels of anxiety (Mehnert et al., 2014). These
onditions can negatively affect clinical factors such as treatment
ompliance, quality of life and survival. Reduced cognitive and sex-
al function, and fatigue, can be long-term effects in patients with
olorectal cancer even years after diagnosis and treatment, disrupt-
ng psychosocial wellbeing (El-Shami et al., 2015).
The role of the psycho-oncologist is to:
Ensure that psychosocial distress, psychological disorders and
psychosocial needs are identiﬁed by screening, and considered
by the MDT
Promote effective communication between patients, family
members and healthcare professionals
Support patients and family members to cope with multifaceted
disease effects
Evaluate psychosocial care programmes.
Essential requirements:
Access to a self-administered psychological assessment tool (‘dis-
tress thermometer’) and psychosocial care must be guaranteed at
all stages of the disease and its treatment
Psycho-social care for patients and their families must be pro-
vided by psycho-oncologists to ensure comprehensive cancer
care.
.5. Diet and nutrition
Qualiﬁed nutritional specialists are required in the pre-, -peri-
nd postoperative settings of CRC, and also during adjuvant treat-
ent of advanced CRC. The role of the nutritional specialist is to
revent or treat malnutrition, improve or stabilise the nutritional
tate, maintain performance status, support the tolerability of ther-
peutic measures, and so positively inﬂuence the course of disease
Arends et al., 2016; Bozzetti et al., 2009).
Essential requirements:
Nutritional advice must be given to minimise side-effects after
surgery such as intestinal discomfort, lack of appetite and risk of
malnutrition
The nutritionist must perform regular nutritional screenings,
starting with the ﬁrst presentation of the patient, to determine
a compromised nutritional state as soon as possible. The screen-
ing should use validated instruments such as NRS-2002, MUST or
SGA
In cases of malnutrition, a structured assessment must be per-
formed including assessing food intake, total and lean body mass
(e.g. by BIA analysis), performance status and systemic inﬂam-
mation (e.g. by assessing CRP and/or albumin levels in blood)
The nutritionist must also determine the reasons for compro-
mised food intake and take appropriate measures to counteract
them. This includes enteral and parenteral nutrition in the hos-
pital and at home.gy/Hematology 110 (2017) 81–93 89
5.6. Palliative care
More than one third of the CRC patients suffer from incurable
disease and need palliative care in conjunction with cancer treat-
ments to manage distressing clinical complications and symptoms,
and improve their quality of life and that of their families (Temel
et al., 2010; Quill and Abernethy, 2013; Hui et al., 2015). Palliative
care, as deﬁned by the World Health Organization, applies not only
at end of life but throughout cancer care (see http://www.who.int/
cancer/palliative/deﬁnition/en).
The role of the palliative specialist is to:
• Be responsible for specialist palliative care and make recommen-
dations to other specialists about symptom control and other
conditions
• Identify patients who need palliative care through the system-
atic assessment of distressing physical, psychosocial and spiritual
problems
• Treat disease and treatment-related symptoms such as pain,
bowel dysfunction and dyspnoea, and offer psychosocial and spir-
itual care
• Incorporate support for family members
• Provide early integrated palliative care in conjunction with can-
cer speciﬁc treatments
• Provide end-of-life care, working with primary care palliative
care providers.
Essential requirements:
• There must be a palliative care unit with a specialist team that
includes palliative care physicians and specialist nurses, working
with social workers, chaplains, psychotherapists, physiothera-
pists, occupational therapists, dieticians, pain specialists and
psycho-oncologists
• All CRC patients with severe symptoms or suffering, or patients
with metastatic disease and short life expectancy (under a year),
irrespective of the cancer-speciﬁc treatment plan, must be intro-
duced to a specialist palliative care team
• To ensure the continuity of care at home, the palliative care team
must work with primary care providers.
5.7. Rehabilitation and survivorship
Survivorship, rehabilitation and supportive care are major
issues for CRC patients and are increasing in importance as the
number of survivors rises. Some CRC survivors suffer for many
years from ongoing conditions that result from the primary treat-
ment of their cancer, such as a permanent stoma, bowel and urinary
problems, and sexual dysfunction.
Late-effects from treatments and how patients’ lives are affected
are not well understood. Cancer rehabilitation is crucial in helping
people adapt to their condition and maximise function, indepen-
dence and quality of life. It is every professional’s responsibility to
anticipate rehabilitation needs before treatment and offer appro-
priate rehabilitative care to prevent, restore, support or palliate
(Stubbleﬁeld et al., 2013; Berg et al., 2016; Scott et al., 2013).
Return-to-work remains an important topic for many cancer
patients when they are identiﬁed as ‘cured’ cases. Work is not only
an issue with ﬁnancial implications, but can also help patients to
feel better psychologically.Essential requirements:
• A multidisciplinary team involving clinicians, nurses, psycholo-
gists and physiotherapists must discuss with patients how their
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functioning will develop as the treatment goes and the types of
help available for them, e.g. physical activity.
Patients and their families must also be informed about potential
treatment late-effects and how these can be monitored and tack-
led, e.g. through good post-treatment care and regular screening
Rehabilitation and survivorship must be integrated into care
pathways to ensure the best possible care continues beyond
active curative treatment
Professionals must use a person-centred, goal-setting approach,
empowering the patient and their carers to take control of their
rehabilitation
Professionals need to adjust their psychosocial and other sup-
portive care keeping in mind the problems faced by CRC cancer
survivors, including ostomy/bowel problems (McMullen et al.,
2016) sexual concerns (Downing et al., 2015) and fatigue (Mota
et al., 2012)
Employers and trade unions must encourage early discussions
about the possibilities for employees to return to work after sick
leave, such as changing job duties and working hours
Rehabilitation and survivorship of cancer must be integrated into
national cancer plans.
.8. Neuro-oncology
Colorectal cancer can metastasise into the brain, although rarely.
ther types of CRC metastasis relevant to neurology are to the
pinal cord, and also local spread involving nervous tissue (e.g.
he sacral plexus). A frequent nervous system side-effect from cer-
ain CRC drugs is peripheral neuropathy (Grisold et al., 2012; Park
t al., 2013) which is not always reversible and late effects are
ncreasingly observed in long-term survivors. Sensory symptoms,
lumsiness, ataxia and neuropathic pain are other disabling symp-
oms.
The role of the neurologist is to:
Advise and guide in metastasis to the nervous system
Advise on neurotoxic effects of chemotherapy
Assess and treat neuropathies, and take part in pain analysis and
treatment (in several countries these can also be the responsibil-
ity of pain specialists).
Essential requirements:
For patients presenting with neurotoxic effects access to a neu-
rologist must be guaranteed, not necessarily on site
Neurologists must assess neurologic symptoms and treatment
effects in CRC patients, with a focus on toxicity and changes/side-
effects on the central nervous system (CNS) and peripheral
nervous system. The use of simple composite scores for neu-
ropathies is recommended.
. Other essential requirements
.1. Patient involvement, access to information and transparency
Patients must be involved in every step of the decision-making
process. Their satisfaction with their care must be assessed
throughout patient care pathways. It is also essential that patient
support organisations are involved whenever relevant. Patients
must be offered information to help them understand the treat-
ment process from the point of diagnosis. They must be supported
and encouraged to engage with their health team to ask questions
and obtain feedback on their treatment wherever possible.gy/Hematology 110 (2017) 81–93
• Conclusions on each case discussion must be made available to
patients and their primary care physician. Advice on seeking sec-
ond opinions must be supported.
• Cancer healthcare providers must publish on a website, or make
available to patients on request, data on centre/unit performance,
including:
© Information services they offer
© Waiting times to ﬁrst appointment
© Pathways of cancer care
© Numbers of patients and treatments at the centre
© Clinical outcomes
© Patient experience measurements
© Incidents/adverse events.
6.2. Auditing, performance measurement, quality assurance and
accreditation
• The expanded MDT  must meet at least once a year to review the
activity of the previous year, discuss changes in protocols and
procedures, and improve the performance of the unit/centre.
• To properly assess quality of CRC care, three categories of out-
comes must be measured and collected in a database at the level
of the CRC centre, and regionally and/or nationally:
© Clinical outcomes
© Process outcomes
© Patient-reported outcomes (PROs).
Data measured and collected varies from one country to another
but it is recommended that the following outcome data are system-
atically measured and collected (see also ‘Further quality and audit
resources’, below):
• 5-year overall survival rate
• Complications
• % of preoperative patients discussed in the MDT
• % of postoperative patients discussed in the MDT.
The expert group also recommends that centres develop perfor-
mance measurement metrics based on the essential requirements
in this paper.
• The ECCO expert group also recommends that further attention
must be given to patient reported outcome measures (PROMs),
to not only agree on which tools should be used, but also to use
PROs more systematically as part of discussions and evaluation
within the MDT.
To ensure appropriate, timely and high-quality care, a quality
management system (QMS) must be in place. It must involve clini-
cal care, strategic planning, human resource management, training
etc. The QMS  must be accountable at an institutional manage-
ment level and based on written and agreed documentation such
as guidelines, protocols, patient pathways, structured referral sys-
tems, and standard operating procedures (SOPs).
The QMS  must ensure continuity of care for patients, involve-
ment of patients in cancer care pathways, and reporting of patient
outcomes and experience. As part of a QMS, an effective data
management and reporting system, and an internal audit sys-
tem, are necessities. Where available, external national audit and
certiﬁcation systems are to be followed. The ECCO expert group
also strongly recommends participation in international accredita-
tion programmes (e.g. Organisation of European Cancer Institutes
(OECI) accreditation: see http://oeci.selfassessment.nu/cms) (Wind
et al., 2016).
At European level, a consortium of cancer societies, including
ECCO, have started a quality improvement programme, European
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egistration of Cancer Care (EURECCA), which has initially focused
n colorectal cancer. A paper from 2014 (Breugom et al., 2014) notes
hat audits have most commonly focused on surgery, and on rectal
urgery in particular, owing to poor outcomes in the 1990s. Several
ountry audit programmes are mentioned – the longest standing
s the Norwegian Colorectal Cancer Project, which began in 1993.
URECCA has been identifying a core dataset for audit registries,
nd held a consensus meeting to draw up CRC multidisciplinary
uidelines (van de Velde et al., 2014).
It is noted that quality assurance is high in clinical trials of CRC,
uch as when research was carried out on combining radiotherapy
ith total mesorectal excision (TME) surgery in rectal cancer, and
ndeed quality assurance is most advanced in surgery generally.
he EURECCA 2014 paper notes that patients treated in trials have
etter outcomes, and discusses how quality assurance is develop-
ng in other disciplines such as radiation oncology, pathology and
edical oncology − in the latter, some studies have indicated that
bout half of patients have received non-evidence based schedules.
And not least, quality assurance applies to the management of
DTs and also to demonstrating cost-effectives of quality improve-
ents.
.2.1. Further quality and audit resources
The National Bowel Cancer Audit in England and Wales
(Healthcare Quality Improvement Partnership, 2015) reports on
care pathways, referral sources, how patients are treated, the
outcomes of surgery and survival, and will include linkages to
chemotherapy, radiotherapy and palliative care databases. It uses
quality standards from both NICE and the Association of Colo-
proctology of Great Britain and Ireland.
Germany has a voluntary certiﬁcation system for cancer institu-
tions including those that qualify as a multidisciplinary bowel
cancer centre. This system currently covers about half of colon
cancers and the majority of rectal cancers treated in Germany.
The certiﬁcation guideline for CRC has 197 qualitative and quan-
titative requirements, such as minimum surgery volumes, as
discussed in a paper that concludes that certiﬁcation leads to
a better concentration of treatment-related issues (Jannasch
et al., 2015). There are regular benchmark reports (Wesselman
et al., 2014) on the performance of these centres on all items
audited annually, and quality indicators are regularly reported
and updated. Another requirement for certiﬁcation is that 5% of
CRC patients are included in clinical trials.
The Dutch Surgical Colorectal Audit in hospitals in the
Netherlands increased guideline compliance for diagnostics, pre-
operative multidisciplinary meetings and standardised reporting,
while complication, re-intervention and postoperative mortality
rates decreased signiﬁcantly (Van Leersum et al., 2013).
A study that developed evidence-based quality indicators for CRC
in a population setting was published by a Swiss group in 2013
(Bianchi et al., 2013). An important message is that older people
must be included.
A systematic review of the literature on patterns of CRC care in
Europe, Australia and New Zealand found there is less treatment
for older people and for the less well-off, although wide vari-
ability in data collection, health systems and populations made
comparisons challenging (Chawla et al., 2013).
.3. Cancer education and training
It is essential that each CRC centre provides professional clin-
cal and scientiﬁc education on the disease and that at least one
erson is responsible for this programme. Healthcare professionals
orking in CRC must also receive training in psychosocial oncology,
alliative care, rehabilitation and communication skills. Such train-gy/Hematology 110 (2017) 81–93 91
ing must also be incorporated into postgraduate and undergraduate
curriculums for physicians, nurses and other professionals.
6.4. Clinical research
Centres treating CRC must have clinical research programmes
(either their own  research or as a participant in programmes led
by other centres). The research portfolio should have both inter-
ventional and non-interventional projects and include academic
research.
The MDT  must assess all new patients for eligibility to take
part in clinical trials at the centre or in research networks. For
CRC, centres should have at least 10% of all patients included in
their research projects or in research performed in other centres.
Researchers at other centres should be considered as part of the
expanded MDT  for at least annual discussion of clinical trial par-
ticipation. Recent research demonstrates that institutions active
in research achieve better outcomes for the entire patient group
rather than just the research participants (Downing et al., 2016).
Older adults are currently underrepresented in cancer clin-
ical trials despite having a disproportionate burden of disease
(Kaz´mierska, 2013). Strategies to increase the participation of older
adults in clinical trials must be implemented and trials designed to
take into account their needs.
7. Conclusion
Taken together, the information presented in this paper pro-
vides a comprehensive description of the essential requirements
for establishing a high-quality CRC service. The ECCO expert group
is aware that it is not possible to propose a ‘one size ﬁts all’ system
for all countries, but urges that access to multidisciplinary units or
centres must be guaranteed for all those with CRC.
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